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Semiphysiologically Based Pharmacokinetic Model for
Midazolam and CYP3A Mediated Metabolite 1-OH-
Midazolam in Morbidly Obese and Weight Loss Surgery
Patients
MJE Brill1,2, PAJ V€alitalo1, AS Darwich3, B van Ramshorst4, HPA van Dongen5, A Rostami–Hodjegan3, M Danhof1 and
CAJ Knibbe1,2*
This study aimed to describe the pharmacokinetics of midazolam and its cytochrome P450 3A (CYP3A) mediated metabolite 1-
OH-midazolam in morbidly obese patients receiving oral and i.v. midazolam before (n5 20) and one year after weight loss
surgery (n5 18), thereby providing insight into the influence of weight loss surgery on CYP3A activity in the gut wall and
liver. In a semiphysiologically based pharmacokinetic (semi-PBPK) model in which different blood flow scenarios were
evaluated, intrinsic hepatic clearance of midazolam (CLint,H) was 2 (95% CI 1.40–1.64) times higher compared to morbidly
obese patients before surgery (P< 0.01). Midazolam gut wall clearance (CLint,G) was slightly lower in patients after surgery
(P> 0.05), with low values for both groups. The results of the semi-PBPK model suggest that, in patients after weight loss
surgery, CYP3A hepatic metabolizing capacity seems to recover compared to morbidly obese patients, whereas CYP3A
mediated CLint,G was low for both populations and showed large interindividual variability.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 20–30; doi:10.1002/psp4.12048; published online 18 December 2015.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  Midazolam systemic plasma clearance increases upon
weight loss surgery, whereas midazolam oral bioavailability is unchanged. • WHAT QUESTION DID THIS STUDY
ADDRESS?  How does weight loss surgery affect CYP3A activity in the gut wall and liver? • WHAT THIS STUDY ADDS
TO OUR KNOWLEDGE  This study shows that intrinsic hepatic metabolism of midazolam into 1-OH midazolam (hepatic
CYP3A activity) is 1.5 times increased in patients after weight loss surgery, whereas intrinsic metabolism of midazolam into
1-OH midazolam in the gut wall was low and highly variable in both patient groups. • HOW THIS MIGHT CHANGE CLINICAL
PHARMACOLOGY AND THERAPEUTICS  Weight loss surgery substantially increases hepatic CYP3A activity and
therefore may increase the plasma clearance of CYP3A-mediated drugs. However, extrapolations should be performed with
caution, because it is unclear how hepatic blood flow and perfusion is affected after weight loss surgery.
Weight loss surgery or bariatric surgery is widely and increas-
ingly applied to treat morbid obesity (body mass index
>40 kg/m2).1–3 This type of surgery may profoundly affect
drug pharmacokinetics, as the procedure reduces the stom-
ach to a small pouch and, in case of a Roux and Y-gastric
bypass (RYGB), 75–150 cm of the initial part of the small
intestines, including the duodenum, is bypassed.4,5 In addi-
tion, patients lose on average 32% of their body weight within
one year,6 which may affect clearance and the distribution of
drugs as well.7
Previously, we showed in a population pharmacokinetic
(PK) analysis that plasma clearance (CL) of the cytochrome
P450 3A (CYP3A) substrate midazolam is 1.7 times
increased in patients after a weight loss procedure in com-
parison to morbidly obese patients, whereas oral bioavailabil-
ity (Ftotal) was unaltered.
8 Similar results have been reported
before for RYGB patients in comparison with age, gender,
and body mass index-matched control patients.9 Although it
is well known that CYP3A resides both in the gut and in the
liver, these analyses that use total oral bioavailability (Ftotal)
as parameter do not allow for a distinction between the contri-
bution of presystemic gut and presystemic liver metabolism.
More specifically, oral bioavailability (Ftotal) may be deduced
to its individual contributors, which are the fraction absorbed
(Fa), the fraction escaping gut wall metabolism (FG), and the
fraction escaping first pass hepatic metabolism (FH). As mid-
azolam is a highly soluble and permeable drug, Fa is
assumed to be equal to one in morbidly obese patients
before and after surgery.10,11 Keeping in mind the reported
increase in midazolam systemic plasma clearance after a
weight loss surgery,9,12 FH is expected to decrease after
weight loss surgery. So, given the unchanged total bioavaila-
bility (Ftotal) identified in these patients,
8 it may be hypothe-
sized that the midazolam fraction escaping gut wall (FG)
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increases one year after weight loss surgery (see Supple-
mentary Information S1). In theory, such an increase in FG
upon weight loss surgery may be attributed to the 75–150 cm
bypass of the small intestine during an RYGB surgery4
potentially causing reduced (intrinsic) CYP3A clearance in
the gut.
Knowledge on the exact influence of a weight loss sur-
gery on hepatic and gut wall CYP3A clearance is important
because 30% of all clinically used drugs are metabolized
via this enzyme.12 To fully characterize the influence of
weight loss surgery on CYP3A-mediated drug metabolism
in both the gut wall and the liver, a semiphysiologically
based pharmacokinetic (semi-PBPK) model taking into
account these distinct processes needs to be applied to
both midazolam and the CYP3A-mediated metabolite
1-OH-midazolam concentrations obtained after oral and i.v.
administration in these populations.13,14 Such a semi-PBPK
model consists of a compartment representing the gut wall,
the portal vein, and the liver, and an empirical compartment
model for midazolam and 1-OH-midazolam, representing
the rest of the body. The model is parameterized on the
basis of intrinsic clearance (CLint) for both the gut and the
liver, blood flow, and fraction unbound in the blood or gut
wall. In this model, intrinsic midazolam clearance in the
liver or gut wall represents the capacity of the liver or gut
wall to metabolize midazolam into 1-OH-midazolam and
therefore represents CYP3A activity in these respective
organs.
In this study, we aimed to describe both midazolam and its
CYP3A-mediated metabolite 1-OH-midazolam in morbidly
obese patients before and one year after weight loss surgery
after both oral and i.v. administration using a semi-PBPK
model, ultimately to evaluate how the intrinsic CYP3A activity
in the gut wall and liver are affected by weight loss surgery
and (loss of) body weight. In addition, the results are used to
explore to what extent these results may affect other CYP3A
substrates used after weight loss surgery.
METHODS
Study design and patients
In this study, data are used from a prospective observatio-
nal cohort study in 20 morbidly obese patients at the day of
laparoscopic weight loss surgery of whom 18 patients were
studied again one year later (NTC01519726, EudraCT
2011-003293-93). Study design and characteristics have
been described before and are repeated briefly below.8
In the study, morbidly obese patients undergoing a laparo-
scopic gastric bypass or sleeve surgery were eligible for inclu-
sion. Patients were excluded if they used CYP3A-inducing or
inhibiting medication,15, used products containing grapefruit,
wild grape, banpeiyu, pomegranate, star fruit, or blackberry
within two weeks before the study, were pregnant, were
breastfeeding, or suffered from renal insufficiency (epidermal
growth factor receptor modification of diet in renal disease-4
<60 mL/min). Before participation, all patients gave written
informed consent. One year after the weight loss procedure,
18 of the 20 patients were restudied using the same study
design. At both occasions, patients received 7.5 mg oral and
5 mg i.v. midazolam separated by 1606 48 minutes. Per
patient and occasion, a mean of 22 blood samples were col-
lected to measure both midazolam and 1-OH midazolam con-
centrations. Plasma concentrations were measured using a
method described before.16 For 1-OH midazolam, the lower
limit of quantification was 0.9 ng/mL and intra-assay and inter-
assay coefficients of variation were 6.3% and 4.5%.
The study was approved by the local human research and
ethics committee (NL35861.100.11) and was conducted
according to the principles of the Declaration of Helsinki (ver-
sion 22-10-2008) and in accordance with the Medical
Research Involving Human Subjects Act (WMO) of the
Netherlands.
Population pharmacokinetic modeling
Population PK modeling was performed using NONMEM
7.3,17 ADVAN 6 (PsN version 3.6.2), Pirana (version 2.9.0),
and R (version 3.1.2) to visualize the data. Different struc-
tural models were tested to fit the midazolam and 1-OH-
midazolam data from morbidly obese patients before and
after weight loss surgery.
First, a regular population PK model was applied with a
two-compartment model for 1-OH-midazolam, a three-
compartment model for midazolam, and a transit compart-
ment model for midazolam oral absorption in which the oral
absorption rate (Ka) was set equal to the transit compart-
ment rate (Ktr; intermediate model, Figure 1a). This model
was based on earlier work on the PKs of midazolam not
involving the 1-OH-midazolam metabolite.8
Second, a semi-PBPK model was applied to describe the
data (semi-PBPK model, Figure 1b). The structural semi-
PBPK model was adopted from Yang et al.13 (2003) and
Frechen et al.14 (2013) and consisted of a compartment rep-
resenting the gut wall, the portal vein, and the liver, and an
empirical compartment model for midazolam and 1-OH mid-
azolam, representing the rest of the body. In order to reduce
runtimes, midazolam and 1-OH-midazolam were assumed
to reach an instant equilibrium in the gut wall, portal vein,
and liver compartment, which resulted in a simplified semi-
PBPK model (see Supplemental Information S2). For mid-
azolam, a three-compartment model was used and for mida-
zolam oral absorption a transit compartment model in which
the oral absorption rate was equalized to the transit com-
partment rate (Ktr)
18 was used. For 1-OH-midazolam, a two-
compartment model was applied.
In the semi-PBPK model, hepatic (EH) and gut wall
extraction (EG) of midazolam were defined as the input for
the liver and gut wall compartment of the 1-OH-midazolam
model, respectively. Hepatic extraction of midazolam (EH)
and 1-OH-midazolam (EH,1-OH) was defined by the well-
stirred model:
EH5
CLint;H  fuB
QH;B1ðCLint;H  fuBÞ (1)
where CLint,H is the intrinsic hepatic clearance based on
unbound blood concentrations, fuB is the unbound concen-
tration in blood, and QH,B is the hepatic blood flow.
The fraction escaping hepatic metabolism (FH) was
defined as:
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FH512EH (2)
For gut wall midazolam metabolism into 1-OH-midazolam
(EG) the QGut model was used
19:
EG5
CLint;G  fuG
QGut1ðCLint;G  fuGÞ (3)
where Clint,G is the intrinsic gut wall clearance based on
unbound blood concentrations, fuG is the unbound drug
concentration in the gut wall, and QGut is defined by
19:
QGut5
Qvilli  CLperm
Qvilli1CLperm
(4)
where Qvilli is the villous blood flow and CLperm is a term
defining the permeability of the drug through the entero-
cytes in the gut wall. The fraction escaping gut wall metab-
olism was defined as:
FG512EG (5)
Gut wall extraction of 1-OH-midazolam (EG, 1-OH) was
defined by:
EG;12OH5
CLint;G;12OH  fuG;12OH
QVilli1ðCLint;G;12OH  fuG;12OHÞ (6)
Systemic plasma clearance (CLH) was derived from the
hepatic midazolam intrinsic clearance and hepatic blood
flow using20:
CLH5
QH;B  fuB  CLint;H
QH;B1fuB  CLint;H=ðCB=CPÞ (7)
In which CB/CP is the blood to plasma ratio.
Values used for the drug parameters are listed in Table 1.
The fraction of midazolam absorbed (Fa) was fixed to one and it
was assumed that no protein binding occurred in the gut wall
(Table 1). As midazolam is an intermediate extraction ratio drug
(EH5 0.421–23), for the hepatic blood flow (QH) three different
scenarios were explored, including QH based on allometric
scaling (scenario 1),24, QH based on a model for cardiac output
in obese and morbidly obese patients (scenario 2),25,26 and a
QH that was the same before and after weight loss surgery
(scenario 3), see Table 1.
Discrimination between different structural models was
made by comparison of the objective function value (OFV; i.e.,
22 log likelihood). A P value< 0.05, representing a decrease
of 3.84 in the OFV between nested models for one degree of
freedom, was considered statistically significant. In addition,
goodness-of-fit plots (observed vs. individual-predicted con-
centrations, observed vs. population-predicted concentrations,
conditional weighted residuals vs. time, and conditional
weighted residuals vs. population-predicted concentrations
plots) of midazolam and 1-OH-midazolam were used for diag-
nostic purposes. Furthermore, the confidence interval (CI) of
the parameter estimates, the correlation matrix, and visual
improvement of the individual plots were used to evaluate the
models. The internal validity of the population PK model was
assessed by the bootstrap resampling method using 500
replicates.
For the statistical model, the individual parameter esti-
mate (empirical Bayes estimate or post hoc value) of the
ith individual was modeled according to:
hi5hmean3e
gi (8)
where hmean is the population mean, and gi is a random variable
for the ith individual with a mean of zero and variance of x2,
assuming log-normal distribution in the population. For residual
Figure 1 Schematic representation of the intermediate population pharmacokinetic model (a) and semi-PBPK model (b) for midazolam
and its 1-OH-midazolam metabolite (1-OH). B, blood; CLint, intrinsic clearance; E, extraction ratio; G, gut wall; F, bioavailability; fa, frac-
tion absorbed into the gut wall; fu, fraction unbound; H, hepatic; HA, hepatic artery; Ka, oral absorption rate; Ktrantsits, transit compart-
ment rate; Q is blood flow (Qvilli, QPV, QHA, QH) or intercompartmental clearance (Q1 and Q2); PV, portal vein.
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variability, resulting from assay errors, model misspecifications
and other unexplained sources, a proportional error model was
used. The jth observed midazolam concentration of the ith indi-
vidual (Yij) is described by:
Yij5Cpred;ij3ð11eijÞ (9)
where Cpred,ij is the individual predicted midazolam concen-
tration of the ith individual at the jth time, and eij is a ran-
dom variable with a mean of zero and variance of r2.
Data below the limit of quantification of the bioanalysis
assay were provided by the laboratory and included in the
dataset. Data below the limit of detection, defined as 30%
of the lower limit of quantification, were deleted from the
data set (5.7% for midazolam and 8.9% for 1-OH-
midazolam).27
Based on our earlier PK analysis for midazolam, body
weight on midazolam central, and peripheral volume of dis-
tribution for morbidly obese patients, and a separate
parameter estimate for midazolam oral absorption rate and
intercompartmental clearance in morbidly obese and weight
loss patients were included in the model.8 After inclusion of
these midazolam covariates, a single covariate, the influ-
ence of weight loss surgery, was tested on midazolam gut
wall and hepatic intrinsic clearance (CLint). The binary cova-
riate before/after weight loss surgery was plotted independ-
ently against the individual post hoc values and eta
estimates of midazolam intrinsic clearance estimates to vis-
ualize potential relations. The covariate “before/after weight
loss surgery” was tested by means of a separate parameter
or using the following equation:
Pi5Pp3Z
COV (10)
where Pi and Pp represent individual and population param-
eter estimate, Z the estimated factor of increase or
decrease for the patients subgroup with COV equaling one.
The covariate was separately entered onto CLint,G or CLint,H
and statistically tested (P<0.05) by use of the OFV and, if
applicable, the 95% CI of the additional parameter. In addition,
if applicable, it was evaluated whether the interindividual vari-
ability (eta) in the parameter concerned decreased upon inclu-
sion of the covariate on the parameter and whether the trend in
the eta vs. covariate plot had resolved.
SimCYP simulations
The influence of weight loss surgery on mean systemic
plasma clearance values of other CYP3A substrates was
evaluated using the morbidly obese population in the Sim-
CYP software and manipulation of the value for CYP3A
hepatic abundance.28,29 For each CYP3A-mediated drug,
10 trials of 10 individuals were simulated.
RESULTS
The demographic data of the patients included in this analysis
are provided in Table 2. Figure 2a shows the goodness-of-fit
plots of the midazolam and 1-OH-midazolam plasma concen-
trations of both morbidly obese and weight loss patients on the
basis of the regular population PK model, as shown in
Figure 1a (intermediate model). These goodness-of-fit plots
show that after the oral dose, midazolam concentrations were
Table 1 Values used for drug parameters and for three hepatic blood flow scenarios used in the semi-PBPK model
Parameter (unit)
Reference
Scenario 1 Allometric scaling
of the hepatic blood flow24
Scenario 2 Hepatic blood flow as
a fraction of cardiac output25,26
Scenario 3 One hepatic blood
flow for all individuals
Midazolam
fa 1
22
B:P 0.6622,41
fuG 1
fuB 0.0303
41
CLperm (L/min) 0.177
19
1-OH-midazolam
B:P 1
fuG, 1-OH 1
19
fuB, 1-OH 0.106
42
CLperm 1
Blood flows
Cardiac output (L/min) - (9119– EXP (9.164122.9 *1022 *
TBW13.91 *1024 *
TBW2121.91 *1026 * TBW3)/1000
7
Qhepatic (L/min) 3.75 * TBW
0.75 0.25 * CO26 0.25 * CO26
Qhepatic artery 0.25 * Qhepatic
26 0.25 * Qhepatic
26 0.25 * Qhepatic
26
Qportal vein 0.75 * Qhepatic
26 0.75 * Qhepatic
26 0.75 * Qhepatic
26
Qsmall intestine 0.4 * Qhepatic
26 0.1 * CO19,26 0.4 * Qhepatic
26
Qmucosal 0.80 * Qsmall intestine
19 0.80 * Qsmall intestine
19 0.80 * Qsmall intestine
19
Qvilli 0.60 * Qmucosal
19 0.60 * Qmucosal
19 0.60 * Qmucosal
19
B:P, blood to plasma ratio; fa, fraction absorbed in the gut wall; fub, fraction unbound in blood; fug, fraction unbound in gut wall; CLperm, parameter representing
the permeability through the enterocyte; Q, blood flow. The parameter values for midazolam and 1-OH-midazolam apply to all three scenarios.
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over-predicted, whereas midazolam concentrations after the
i.v. dose were underpredicted (Figure 2a). In contrast,
1-OH-midazolam concentrations after oral dose were under-
predicted by the model, whereas 1-OH-midazolam concentra-
tions after i.v. dose were overpredicted. Furthermore, all of the
conditional weighted residuals (CWRES) values stratified by
patient group (obese or bariatric), administration type (oral or
i.v.), and compound (parent or metabolite) were significantly dif-
ferent from zero (P< 0.001 each) for the intermediate population
PK model. The obvious misspecification of midazolam and its 1-
OH-midazolam metabolite concentrations indicate the presence
of substantial presystemic 1-OH-midazolam formation after oral
administration and therefore, as a second step, a semi-PBPK
model, including both presystemic midazolam metabolism at gut
wall and hepatic level, was applied (Figure 1b and Supplemen-
tary Information S3). Application of the semi-PBPK model
enabled a substantially improved prediction of midazolam and 1-
OH-midazolam concentrations after both oral and i.v. dose and
led to stratified CWRES) mean values much closer to zero (Fig-
ure 2b).
Upon these findings, the semi-PBPK model was further
explored for covariates, taking into account the different QH
scenarios for obesity (see Methods and Table 3). The influ-
ence of weight loss surgery on midazolam intrinsic gut wall
(CLint, G) and hepatic clearance (CLint, H) was evaluated by
visual inspection of eta vs. covariate plots. Figure 3 shows
a trend of higher CLint,H and slightly lower CLint,G in weight
loss patients in comparison to morbidly obese patients
(Figure 3, upper panels). A separate parameter estimate
for CLint,H for morbidly obese and weight loss patients
showed a 1.52 (with a 95% CI of 1.40–1.64) times higher
intrinsic hepatic clearance in weight loss patients (27
DOFV, P< 0.01 for all QH scenarios) and a small decrease
in interindividual variability (53% relative standard error of
19% vs. 48% (19%) for scenario 1). A separate parameter
estimate for midazolam gut wall intrinsic clearance (CLint,G)
did not significantly improve the model (22 DOFV, P>0.05
for all QH scenarios). The two highest individual estimates
for CLint,G (see Figure 3, lower row, right plot) are two mor-
bidly obese individuals for which the duration in between
oral and i.v. midazolam dose was only 43 and 50 minutes
as compared to a mean of 1716 57 minutes for the other
18 morbidly obese patients. In addition, it seems that also
these two individuals substantially contributed to the uncer-
tainty of the parameter for intrinsic gut wall clearance of 1-
OH-midazolam (CLint,G 1-OH). Upon exclusion of these two
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Figure 2 (a) Goodness-of-fit plots for midazolam (left) and 1-OH-midazolam (right) plasma concentrations for the population PK model
(intermediate model, Figure 1a) for morbidly obese (black dots) and weight loss surgery patients (gray dots), including population pre-
dicted vs. observed plots (upper row), population predicted concentrations vs. conditional weighted residuals (middle row), and time after
oral dose vs. conditional weighted residuals (lower row).
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individuals, the parameter estimate for CLint,G 1-OH changes
from 11.9 L/min (relative standard error of 180%) to 6.7 L/
min (relative standard error of 40%). However, exclusion of
the two individuals resulted in the same final covariate
model, and therefore for the final model all individuals were
kept in the data.
Overall, the different QH scenarios (see Methods)
resulted in slightly different hepatic intrinsic clearance esti-
mates: 16.9 L/min (13%), 17.1 L/min (13%), and 12.6 L/min
(16%) for morbidly obese patients, and 25.6 L/min (16%),
25.7 L/min (16%), and 18.9 L/min (21%) for weight loss
patients for scenarios 1, 2, and 3, respectively, whereas the
observed covariate trend between morbidly obese patients
and weight loss patients was identical for the different sce-
narios. Other model parameters and the goodness-of-fit
plots were very similar across the scenarios. These QH
scenarios were tested to evaluate the influence of QH on
the parameters of the model because there is no consensus
yet on the exact changes in QH upon morbid obesity and sub-
sequent weight loss surgery. Although there is no persuasive
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Figure 2 (Continued). The arrows indicate the direction of model misspecification (b) goodness-of-fit plots for midazolam (left) and 1-
OH-midazolam (right) blood concentrations for the final semi-PBPK model (Figure 1b) for morbidly obese (black dots) and weight loss
patients (gray dots), including population predicted vs. observed plots (upper row), population predicted concentrations vs. conditional
weighted residuals (middle row), and time after oral dose vs. conditional weighted residuals (lower row).
Table 2 Patient characteristics (mean6SD)
Morbidly obese patients
before surgery (n520) Minimum-maximum
Patients after bariatric
surgery (n5 18 of 20) Minimum-maximum
Female/male 12/8 11/7
Age, y 43.66 7.6 26 – 57 45.56 7.4 27 – 58
Body weight, kg 144.46 21.7 112 – 186 98.36 18.0 62 – 138
BMI, kg/m2 47.16 6.5 40 – 68 31.96 5.9 24 – 50
Weight loss, kg – – 44.56 10.2 21 – 58
BMI, body mass index.
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argument for choosing one QH scenario above another, the
final parameter estimates and bootstrap results (98% suc-
cessful) of scenario 1 are presented in Table 3 and goodness-
of-fit plots of this final model are shown in Figure 2b.
The different scenarios for hepatic blood flow slightly
influenced the calculated values for midazolam plasma
clearance, FH and FG, even though the differences between
the morbidly obese patients and weight loss patients
remained quite similar per scenario (Figure 4). In general,
for weight loss patients, higher midazolam plasma clear-
ance (upper row of Figure 4, a median increase of 1.28,
1.34, and 1.33, for scenarios 1, 2, and 3, respectively) and
lower FH (middle row, median decrease of 0.84, 0.83, and
0.88, respectively) was observed. FG seems to be close to
one for weight loss patients, whereas the morbidly obese
patient group exhibits large interindividual variability (lower
row of Figure 4).
Finally, the influence of weight loss surgery on hepatic
CYP3A activity was further explored using the SimCYP simula-
tor.28 Based on the findings for hepatic intrinsic midazolam
clearance of the semi-PBPK model, CYP3A abundances in the
liver of the “morbidly obese population” was 1.5 times increased
and plasma clearance values for midazolam, cyclosporine,
alprazolam, and triazolam were simulated. Figure 5 shows that
this increase in CYP3A abundance resulted in a 1.22 increase
of midazolam plasma clearance and a median 1.41, 1.37, and
1.30 increase of plasma clearance for CYP3A substrates cyclo-
sporine, alprazolam, and triazolam, respectively.
DISCUSSION
In this study, we aimed to characterize the PKs of both
midazolam and its primary CYP3A-mediated metabolite
Table 3 Blood parameter estimates of the final semi-PBPK model including covariates for scenario 1
Parameter Parameter definition Value (RSE %) Bootstrap value (SE)
Midazolam
CLint,H morbidly obese (L/min) Intrinsic hepatic clearance morbidly obese 16.8 (14) 16.9 (2.4)
CLint,H weight loss patients (L/min) Intrinsic hepatic clearance weight loss patients 25.5 (15) 25.4 (4.2)
CLint,G (L/min) Intrinsic gut wall clearance 0.0199 (35) 0.0207 (0.007)
Ka morbidly obese5Ktr (min
21) Oral absorption rate 0.126 (10) 0.126 (0.01)
Ka weight loss patients5Ktr (min
21) Oral absorption rate 0.242 (9) 0.241 (0.02)
Vcentral weight loss patients (L) Central midazolam volume of distribution 66.9 (13) 68.1 (8.7)
Vcentral morbidly obese5Vcentral, 144 kg *(11X (TBW-144))
Vcentral, 144 kg (L)5Vcentral weight loss patients Central midazolam volume of distribution
for a 144 kg individual
66.9 (13) 68.1 (8.7)
X Covariate effect of TBW on Vcentral 0.0435 FIX 0.0435 FIX
Vperi 1 weight loss patients (L) First peripheral volume of distribution 31.0 (19) 32.0 (6.5)
Vperi 1 morbidly obese5Vperi 1, 144 kg *(TBW/144)
Y
Vperi 1, 144 kg (L)5Vperi 1 weight loss patients First peripheral volume of distribution 31.0 (19) 32.0 (6.5)
Y Exponent of covariate function 3.93 FIX 3.93 FIX
Vperi 2 (L)5Vperi 1 * Z Second peripheral volume of distribution
Z 10.8 (13) 11.1 (1.7)
Q1 (L/min) First intercompartmental clearance 1.41 (15) 1.35 (0.2)
Q2 (L/min)5Q1*A Second intercompartmental clearance
A 3.22 FIX 3.22 FIX
1-OH-Midazolam
Vcentral, 1-OH (L) Central volume of distribution 41.7 (11) 41.9 (4.7)
Vperi, 1-OH (L) Peripheral volume of distribution 16.4 (25) 17.4 (4.4)
Q1-OH (L/min) Intercompartmental clearance 0.652 (23) 0.65 (0.15)
CLint,H,1-OH (L/min) Intrinsic hepatic clearance 27.4 (9) 27.2 (2.6)
CLint,G,1-OH (L/min) Intrinsic gut wall clearance 11.9 (180) 4.7*10
22 (7.3*1023)
Interindividual variability
Ka (%) Oral absorption rate 44 (20) 43 (19)
Vcentral (%) Central volume of distribution 63 (49) 61 (38)
Vperipheral 1 (%) First peripheral volume of distribution 113 (24) 115 (49)
CLint,H (%) Intrinsic hepatic clearance 48 (21) 47 (20)
CLint,G (%) Intrinsic gut wall clearance 493 (35) 582 (168)
Residual variability
Morbidly obese patients (%) 32.6 (18) 32.2 (13)
Weight loss patients (%) 23.7 (8) 23.6 (7)
A, factor difference with morbidly obese patients; CLint,G, intrinsic gut wall clearance; CLint,H, intrinsic hepatic clearance; FIX, fixed value; Ka, oral absorption
rate; Ktr, transit compartment rate; Q, intercompartmental clearance; RSE, relative standard error; TBW, total body weight (kg); V, volume of distribution; X,
coefficient of covariate relationship; Y, exponent of covariate relationship.
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1-OH-midazolam after oral and i.v. administration in mor-
bidly obese patients before and one year after weight loss
surgery, ultimately to evaluate how intrinsic CYP3A activity
in the gut wall and liver are affected by weight loss surgery.
We found that midazolam and 1-OH-midazolam concentra-
tions could not be described by a regular compartmental
model (Figures 1a and 2a) because of presystemic forma-
tion of the CYP3A-mediated metabolite 1-OH midazolam
for which a semi-PBPK model (Figures 1b and 2b) was
needed. Using this model, it was found that midazolam
intrinsic hepatic clearance (CLint,H) was 1.52 times (95%
CI, 1.40–1.64) higher in patients after weight loss surgery,
independent of the QH scenario used. In addition, intrinsic
midazolam gut wall clearance (CLint,G) showed a trend
toward lower values in patients after surgery (P>0.05).
Intrinsic hepatic midazolam clearance (CLint,H) represents
the capacity of the liver to metabolize midazolam into
1-OH-midazolam and therefore represents hepatic CYP3A
activity. The estimated CLint,H for weight loss patients (25.6,
25.7, and 18.9 L/min for scenarios 1, 2, and 3, respectively)
was in close agreement with the value reported for healthy
volunteers using a very similar semi-PBPK model (27.3;
90% CI, 24.3–30.7 L/min).14 However, for morbidly obese
patients, CLint,H was lower (16.9, 17.1, and 12.6 L/min for
scenarios 1, 2, and 3, respectively), indicating that hepatic
CYP3A activity is reduced in morbidly obese patients in
comparison to healthy volunteers but normalizes one year
after weight loss surgery. Although this recovery of CYP3A
activity in the liver upon weight loss surgery has not been
reported before, reduced hepatic CLint because of morbid
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obesity is supported by in vitro studies that show that
human liver samples with steatosis exhibit reduced CYP3A
activity in comparison to liver samples without steato-
sis.30,31 Comparing the observed 1.52 times (range,
1.40–1.64) increase in CLint,H after a weight loss surgery
with values for midazolam plasma clearance from earlier
reports on weight loss surgery patients, it seems that this
value closely resembles the previously reported 1.7 times
increase in midazolam plasma clearance (CLplasma).
8,9
However, when calculating midazolam plasma clearance on
the basis of midazolam CLint,H using Eq. 7, we only find a
1.28 increase (scenario 1 and Figure 4). In addition, when
increasing hepatic CYP3A abundance by 1.5 times in the
morbidly obese population of the SimCYP simulator, mida-
zolam plasma clearance only increased 1.22 times. This
implies that the increase in midazolam plasma clearance
after a weight loss surgery cannot be solely attributed to a
normalization or recovery of hepatic CYP3A activity. There-
fore, it may be suggested that another non-CYP3A related
process may be involved. This other process may be
hepatic blood flow (QH) or perfusion.
32 In the case of
patients after weight loss surgery, potentially an improve-
ment in hepatic microcirculation function (i.e., liver perfu-
sion) because of a reduction in fatty liver may result in a
more pronounced increase in midazolam systemic plasma
clearance value of 1.7.33,34 For morbidly obese patients in
comparison with nonobese healthy volunteers, the reduced
hepatic CYP3A activity (1.52; range, 1.40–1.64; reduced
CLint,H) found in this analysis may be compensated by an
increase in hepatic blood flow in comparison to healthy vol-
unteers resulting in a similar plasma midazolam systemic
plasma clearance value compared to healthy volun-
teers.16,35 As such, both changes in CYP3A and liver blood
flow and/or perfusion contribute to the overall effects
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observed in midazolam plasma clearance in morbidly obese
and weight loss patients compared to healthy volunteers.
It seems that information on the hepatic blood flow and
perfusion in patients after weight loss surgery is crucial to
understand the results and to support the above-described
hypothesis that hepatic blood flow or perfusion improves
after weight loss surgery. In addition, for morbidly obese
patients, information on hepatic blood flow and perfusion is
scarce. For this reason, we considered in our analysis dif-
ferent hepatic blood flow scenarios (Table 1, Figure 4),
whereas a choice for any of these or other hepatic blood
flow scenarios cannot be justified. Scenario 1, in which the
hepatic blood flow equation by Brown et al.24 was used,
seems to lead to rather large hepatic blood flow values for
morbidly obese patients (QH5 3.7 L/min at 144 kg). At first
sight, scenario 2 seems more plausible for morbidly obese
patients, as hepatic blood flow values are derived from the
cardiac output function, by the study of Young et al.25 in
which data of morbidly obese patients were included, how-
ever, the QH values for weight loss patients may be consid-
ered too low (QH51.3 L/min at 98 kg), whereas in healthy
volunteers, QH is generally considered to be 1.6 L/min.
Scenario 3, assuming a similar blood flow across all body
weights, may not be so unrealistic considering the fact that the
calculated plasma clearance values are in good agreement
with actual results found in our earlier study (Figure 4).8,9
Future research should elucidate how hepatic blood flow is
affected by morbid obesity and weight loss surgery to be able
to further improve predictions on how CYP3A-mediated
hepatic drug clearance is affected.
Midazolam intrinsic gut wall clearance, CLint,G, was low in
both patient groups in comparison to results from healthy
volunteers that were obtained using a similar semi-PBPK
model (0.0199 (35%) vs. 0.45 (0.37–0.52) L/min, respec-
tively).14 As a result, the derived values for FG were near
one for both patient groups (Figure 4). In addition, a trend
for a lower CLint,G for weight loss patients could be
observed (Figure 3). This result may be attributed to the
75–150 cm bypass of relatively CYP3A rich initial part of
the intestines, which is similar to the mechanism that may
explain the increase in FG for controlled release formulation
for highly permeable CYP3A substrates.36 However, the
trend of lower CLint,G for weight loss patients was not statis-
tically significant. This may be due in part to the high inter-
individual variability in CLint,G observed for both groups. For
morbidly obese patients, the relatively low CLint,G estimate
is in line with the increase in midazolam oral bioavailability
(Ftotal) in comparison to healthy volunteers reported earlier
(0.60 (13%) vs. 0.28 (7%); P< 0.01).16
To further investigate the consequences of 1.52 times
(range, 1.40–1.64 times) increased hepatic CYP3A intrinsic
clearance for other drugs, the SimCYP simulator was used
in which a 1.5 increase in hepatic CYP3A abundance in the
morbidly obese population was mimicked. For the CYP3A
substrates cyclosporine, alprazolam, and triazolam, plasma
clearance was 1.30–1.41 times increased as opposed to
1.22 for midazolam. This difference in impact on plasma
clearance between the drugs may be explained by the dif-
ference in extraction ratio of the substrates. Midazolam is
considered an intermediate extraction ratio drug (EH5
0.4),21–23 whereas cyclosporine, alprazolam, and triazo-
lam are low extraction ratio drugs (EH5 0.05–0.25).
37–39
From these simulations, it can be concluded that the sys-
temic plasma clearance of low extraction ratio CYP3A sub-
strates is increased by at least 1.3 times after weight loss
surgery, whereas, because of the lack of knowledge on
how hepatic blood flow is affected by weight loss surgery,
no definite conclusions can be drawn for CYP3A substrates
with median and higher extraction ratios. Finally, these
exploratory extrapolations should be interpreted with cau-
tion, as it has been shown that the in vivo clearance of
CYP3A probes may correlate poorly.40
Finally, despite the substantial improvement of the
description of both midazolam and 1-OH-midazolam con-
centrations over time by the semi-PBPK model, the model
slightly overpredicted 1-OH-midazolam concentrations after
the i.v. dose for patients after weight loss surgery (Figure 2).
However, this was not expected to influence any of the
conclusions.
We conclude that a semi-PBPK model taking into account
both gut wall and liver processes, adequately describes mid-
azolam and CYP3A-mediated 1-OH-midazolam concentra-
tions after both oral and i.v. administration in morbidly obese
patients before and after weight loss surgery. Using this
model, it was revealed that, in patients one year after weight
loss surgery, CYP3A hepatic intrinsic metabolizing capacity
is recovered in comparison to morbidly obese patients before
weight loss surgery, whereas CYP3A mediated gut wall
intrinsic clearance seems to be lower.
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